52913-14-1

Basic information

• Product Name: HydroxylaMine, O-[(4-Methylphenyl)sulfonyl]-
• Synonyms: HydroxylaMine, O-[(4-Methylphenyl)sulfonyl]-;O-p-Toluenesulfonylhydroxylamine
• CAS NO: 52913-14-1
• Molecular Formula: C₇H₉NO₃S
• Molecular Weight: 187.21626
• Mol File: 52913-14-1.mol
• Article Data: 15

Chemical Properties

• Melting Point: 400-410 °C
• Boiling Point: 500°C (rough estimate)
• Appearance: /
• Density: 1.3553 (rough estimate)
• Refractive Index: 1.6100 (estimate)
• PKA: -2.14±0.70(Predicted)
• CAS DataBase Reference: HydroxylaMine, O-[(4-Methylphenyl)sulfonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: HydroxylaMine, O-[(4-Methylphenyl)sulfonyl]-(52913-14-1)
• EPA Substance Registry System: HydroxylaMine, O-[(4-Methylphenyl)sulfonyl]-(52913-14-1)

Safety Data

• Hazardous Substances Data: 52913-14-1(Hazardous Substances Data)

Usage

General Description

Hydroxylamine, O-[(4-Methylphenyl)sulfonyl]-, also known as methanesulfonyl hydroxylamine, is a chemical compound that is commonly used as a reagent in organic synthesis. It is a water-soluble, crystalline solid that is stable under normal conditions. It is primarily used as a reagent for the conversion of aldehydes and ketones to oximes, and also finds use in the synthesis of heterocyclic compounds and pharmaceuticals. HydroxylaMine, O-[(4-Methylphenyl)sulfonyl]- is also a key intermediate in the production of certain herbicides and insecticides. Additionally, it has potential applications in the field of metallurgy as a corrosion inhibitor. However, it is important to handle this compound with caution as it is a strong reducing agent and can react with oxidizing agents, releasing toxic and flammable gases.

Upstream product

• 58636-95-6 O-p-Toluolsulfonyl-N,N-bis<(trimethylsilyl>-hydroxylamin 
• 64420-86-6 O-p-toluenesulfonyl benzyloxyhydroxamate 
• 98-59-9 p-toluenesulfonyl chloride 
• 895151-10-7 ethyl O-(p-tolylsulfonyl)acetohydroximate 
• 1153-45-3 4-nitrophenyl 4-methylbenzenesulfonate 
• 52913-15-2 N-[[(4-methylphenyl)sulfonyl]oxy]ethanimidic acid ethyl ester 

Downstream Products

• 67342-52-3 acetone oxime-o-p-benzenesulfonic ester 
• 120332-75-4 1-amino-2-cyanoquinolinium perchlorate 
• 82319-29-7 2-amino-3-(4-chlorobenzoyl)isoquinolinium tosylate 
• 120332-81-2 2-amino-3-<3-(trifluoromethyl)benzoyl>isoquinolinium tosylate 
• 138572-28-8 Toluene-4-sulfonate1-amino-2-(2-methoxycarbonyl-phenyl)-pyridinium; 
• 20518-17-6 1-(4-methylphenyl)-1H-pyrazole 
• 1175712-55-6 (2E)-5-methyl-N-{[(4-methylphenyl)-sulfonyl]oxy}-2-nitrohex-2-en-1-amine 
• 82319-72-0 2-(p-chlorobenzoy)lpyridine 
• 82319-60-6 1-amino-2-benzoylpyridinium tosylate 
• 1092536-62-3 2-(3-methoxyphenyl)-7-(morpholin-4-yl)-5-benzylamino-4-cyano-s-triazolo[1,5-a]quinoline hydrochloride 
• 1092536-82-7 2-(3-hydroxyphenyl)-7-(4-methylpiperazin-1-yl)-5-benzylamino-4-cyano-s-triazolo[1,5-a]quinoline 

Relevant articles and documents

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 13. Synthesis and profiling of a novel amminium prodrug of the HIV-1 attachment inhibitor BMS-585248

In vitro studies suggested that the ammonium salt 2 could be a viable prodrug of the HIV-1 attachment inhibitor 1. Increased systemic exposure of the parent drug 1 following oral administration of the amminium salt 2 when compared to similar studies using

1,3,4,5-Tetraamino-1,2,4-triazolium Cation: An Energetic Moiety

The amination of 3,4,5-triamino-1,2,4-triazole with O-tosylhydroxylamine yielded the nitrogen-rich 1,3,4,5-tetraamino-1,2,4-triazolium cation as its tosylate salt. Subsequent metathesis reactions produced energetic salts with various energetic anions, inc

ISOPROPYL TRIAZOLO PYRIDINE COMPOUNDS

The present invention provides a compound of the Formula (I) below: Wherein R1 is selected from the group consisting of H, CH3, CN, CH2CN, C(CH3)2CN, and F; R2 is selected from the group consisting of H, O(C1-C3alkyl)R5, CH2CN, and CN; R3 is selected from the group consisting of H, OCH3, CN, C(CH3)2CN, and CH2CN; R4 is selected from the group consisting of H and CH3; R5 is selected from the group consisting of H, CN, C(CH3)2CN, OCH3, S(O)2CH3, and C(CH3)2OH; provided that at least one selected from the group consisting of R1, R2, R3 and R4 is H; or a pharmaceutically acceptable salt thereof, methods of treating diabetes using the compound and a process for preparing the compound.